Neuroblastoma: Global Pipeline Review, H1 2018 - Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 12, 2018--The “Neuroblastoma - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.
This latest pipeline guide provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neuroblastoma (Oncology) pipeline guide also reviews key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 30, 15, 3, 44, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 5, 14 and 3 molecules, respectively.
Companies MentionedAstraZeneca Plc Autolus Ltd Bayer AG Bellicum Pharmaceuticals Inc Bexion Pharmaceuticals LLC Bio-Cancer Treatment International Ltd BioLineRx Ltd Biotec Pharmacon ASA Boehringer Ingelheim GmbH Bristol-Myers Squibb Co Celgene Corp Celldex Therapeutics Inc Cellectar Biosciences Inc Cielo Therapeutics Inc Cleveland BioLabs Inc EnGeneIC Ltd Epizyme Inc Errant Gene Therapeutics LLC F. Hoffmann-La Roche Ltd GC Pharma GlaxoSmithKline Plc ID Pharma Co Ltd Ignyta Inc Ipsen SA Juno Therapeutics Inc Kazia Therapeutics Ltd Loxo Oncology Inc MacroGenics Inc MediaPharma SRL Merck & Co Inc Morphogenesis Inc Novartis AG Pfizer Inc Sapience Therapeutics Inc Syros Pharmaceuticals Inc
Key Topics CoveredIntroduction Neuroblastoma - Overview Neuroblastoma - Therapeutics Development Neuroblastoma - Therapeutics Assessment Neuroblastoma - Companies Involved in Therapeutics Development Neuroblastoma - Drug Profiles Neuroblastoma - Dormant Projects Neuroblastoma - Discontinued Products Neuroblastoma - Product Development Milestones Appendix
For more information about this report visit https://www.researchandmarkets.com/research/lrqkrz/neuroblastoma?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180612005732/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs,Brain Cancer Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/12/2018 06:31 AM/DISC: 06/12/2018 06:31 AM